Bio-Rad Laboratories (BIO) Projected to Announce Quarterly Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO) is projected to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $1.75 per share and revenue of $623.9890 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 5:00 PM ET.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.97 by ($0.08). The company had revenue of $592.10 million for the quarter, compared to analysts’ expectations of $589.91 million. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.54 earnings per share. On average, analysts expect Bio-Rad Laboratories to post $9 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Bio-Rad Laboratories Trading Up 1.4%

BIO stock opened at $305.97 on Thursday. The company has a market cap of $8.19 billion, a price-to-earnings ratio of 50.41 and a beta of 1.08. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. The business has a fifty day simple moving average of $292.57 and a 200-day simple moving average of $287.48. Bio-Rad Laboratories has a 52 week low of $236.73 and a 52 week high of $343.12.

Institutional Trading of Bio-Rad Laboratories

Institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its holdings in Bio-Rad Laboratories by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,077,072 shares of the medical research company’s stock valued at $326,344,000 after purchasing an additional 14,134 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Bio-Rad Laboratories by 1.7% during the third quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock worth $128,948,000 after purchasing an additional 7,754 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Bio-Rad Laboratories by 2,271.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock worth $111,363,000 after purchasing an additional 380,422 shares in the last quarter. Sei Investments Co. boosted its position in shares of Bio-Rad Laboratories by 6.4% in the third quarter. Sei Investments Co. now owns 282,469 shares of the medical research company’s stock worth $79,199,000 after buying an additional 17,084 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its position in shares of Bio-Rad Laboratories by 9.1% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 259,577 shares of the medical research company’s stock worth $78,649,000 after buying an additional 21,674 shares during the period. 65.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $375.00 to $300.00 in a report on Tuesday, April 7th. Royal Bank Of Canada assumed coverage on Bio-Rad Laboratories in a research note on Friday, May 15th. They issued an “outperform” rating and a $320.00 price objective on the stock. Zacks Research cut Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $303.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.